Opdivo is the first and only treatment to demonstrate superior efficacy in patients with esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiation therapy and resection ...
Recommendation based on positive results from the Phase 3 CheckMate -577 trial in which Opdivo doubled disease-free survival compared to placebo in the all-randomized population If approved, Opdivo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback